


Pilot programme to apply whole genome sequencing for routine cancer care in Korea

01 September 2022 | News

Whole Genome Sequencing captures a near complete overview of genomic characteristics of a tumour in one test



US-based Genome Insight, a cancer whole genome platform company, is launching a pilot programme in Ajou University Medical Center, South Korea to test the use of Whole Genome Sequencing (WGS) in routine cancer care setting.

Cancer patients at various stages in the treatment journey will be eligible to receive WGS testing if the clinician notices potential clinical benefits for that patient. Genome Insight will provide its proprietary cancer WGS analysis and interpretation solution to Ajou University Medical Center.

WGS captures a near complete overview of genomic characteristics of a tumour in one test. It enables discovery of all types of genomic mutations, including single nucleotide variants, copy number alterations, insertions/deletions, and structural variants, many of which are targets for precise diagnosis and treatment but hardly detected by common medical tests. Potential direct benefits of cancer WGS include an opportunity to test new cancer drugs in a clinical trial and the development of new biomarkers for precision oncology.

This pilot programme will give the opportunity for clinicians at Ajou University Medical Center to use WGS as needed to achieve the best treatment outcome. Genome Insight will be providing whole-genome data production, analysis and interpretation results in a timely manner that fits into the clinician's practice. In addition, CancerVision, Genome Insight's genome browser optimized for clinicians, will be provided in clinics to explore each patient's cancer genome space in streamlined graphical user interfaces.

Genome Insight and Ajou University Medical Center will initially target more than 100 patients this year and will consider further extension of the program to benefit more patients.